SEP
ALNY icon

Signature Equity Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Signature Equity Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.12K Buy
17
+2
+13% +$603 ﹤0.01% 987
2026
Q1 		$4.96K Buy
15
+9
+150% +$3.06K ﹤0.01% 966
2025
Q4 		$2.39K Buy
+6
New +$2.65K ﹤0.01% 1176

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's ALNY Position: Q2 2026 in Review

Signature Equity Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 13% in Q2 2026, buying an estimated $603 and bringing the position to 17 shares worth $5.12K. The position accounts for ﹤0.01% of the portfolio, ranked #987.

Signature Equity Partners first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Signature Equity Partners held 17 shares of Alnylam Pharmaceuticals worth $5.12K as of Q2 2026.
  • Signature Equity Partners bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #987 holding.
  • Signature Equity Partners first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.